Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EVOK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEVOKEvoke Pharma$2.60-1.1%$3.04$1.94▼$14.00$3.88M0.04124,695 shs15,610 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEVOKEvoke Pharma0.00%-2.05%-21.63%-4.36%-58.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEVOKEvoke Pharma1.1975 of 5 stars0.05.00.00.02.90.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEVOKEvoke Pharma 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEVOKEvoke Pharma$11.59M0.33N/AN/A$4.74 per share0.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEVOKEvoke Pharma-$5.35M-$2.87N/A∞N/A-43.80%-101.91%-33.75%8/11/2025 (Estimated)Latest EVOK, JPJ, 888, and RNK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025EVOKEvoke Pharma-$0.33-$0.51-$0.18-$0.51$3.32 million$3.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEVOKEvoke PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEVOKEvoke PharmaN/A1.551.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEVOKEvoke PharmaN/AInsider OwnershipCompanyInsider OwnershipEVOKEvoke Pharma2.29%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEVOKEvoke Pharma41.49 million1.40 millionNot OptionableEVOK, JPJ, 888, and RNK HeadlinesRecent News About These CompaniesEvoke Pharma (NASDAQ:EVOK) Share Price Passes Below Two Hundred Day Moving Average - Should You Sell?June 26, 2025 | americanbankingnews.comBreakeven On The Horizon For Evoke Pharma, Inc. (NASDAQ:EVOK)June 14, 2025 | finance.yahoo.comEvoke Pharma Inc.June 8, 2025 | wsj.comEvoke Pharma Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | globenewswire.comInizio Evoke appoints Tristen George and Kevin Kaniuga as executive creative directorsMay 10, 2025 | pmlive.comPEvoke Pharma Announces Presentation of New Research on Tardive Dyskinesia at Digestive Disease Week 2025April 30, 2025 | nasdaq.comEvoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025April 28, 2025 | globenewswire.comevoke makes a steady exit from the Q1 starting gateApril 25, 2025 | proactiveinvestors.co.ukWilliam Hill owner Evoke falls at the first-quarter updateMarch 26, 2025 | proactiveinvestors.co.ukEvoke Pharma, Inc. (NASDAQ:EVOK) Just Reported And Analysts Have Been Cutting Their EstimatesMarch 16, 2025 | uk.finance.yahoo.comEarnings call transcript: Evoke Pharma Q4 2024 reports strong sales growthMarch 15, 2025 | uk.investing.comQ4 2024 Evoke Pharma Inc Earnings CallMarch 14, 2025 | finance.yahoo.comEvoke Pharma, Inc. (EVOK) Q4 2024 Earnings Call TranscriptMarch 13, 2025 | seekingalpha.comEvoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides ...March 13, 2025 | gurufocus.comEvoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 13, 2025 | globenewswire.comEvoke Pharma, Inc. to Announce Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025March 6, 2025 | quiverquant.comQEvoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025March 6, 2025 | globenewswire.comEvoke Pharma, Inc. Appoints Greg Pyszczymuka to Board of Directors, Strengthening Commercial StrategyFebruary 24, 2025 | quiverquant.comQEvoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of DirectorsFebruary 24, 2025 | globenewswire.comWilliam Hill owner Evoke expects earnings to beat market forecastsJanuary 17, 2025 | proactiveinvestors.co.ukMedia Sentiment Over TimeEVOK, JPJ, 888, and RNK Company DescriptionsEvoke Pharma NASDAQ:EVOK$2.60 -0.03 (-1.14%) As of 03:59 PM EasternEvoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 S&P 500 All-Time Highs: 5 Catalysts Driving It Higher The Top Insider Sells From Q2: Buy, Sell, or Hold? 5 High-Yielding ETFs to Buy and Hold Forever Why BigBear.ai Could Rally 100% and Catch Palantir Soon Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Alphabet’s Waymo and Services Beginning to Feel the Pressure? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
